Pharmacologic treatment of depression in late life

CMAJ. Canadian Medical Association Journal

Volumn 157, Issue 8, 1997, Pages 1061-1067

  Flint, Alastair J ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT;

AGE; AGED; COGNITIVE DEFECT; CONSTIPATION; DEPRESSION; DROWSINESS; DRUG CHOICE; FOLLOW UP; HUMAN; INAPPROPRIATE VASOPRESSIN SECRETION; ORTHOSTATIC HYPOTENSION; PATIENT REFERRAL; RECURRENCE RISK; RECURRENT DISEASE; RELAPSE; REVIEW; TACHYCARDIA; URINE RETENTION; VISUAL IMPAIRMENT; WEIGHT GAIN; XEROSTOMIA;

EID: 0030821048     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington: The Association; 1994.
2. Blazer DG. Epidemiology of late-life depression. In: Schneider LS, Reynolds CF, Lebowitz BD, Friedhoff AJ, editors. Diagnosis and treatment of depression in late life. Washington: American Psychiatric Press; 1994. p. 9-19.
3. NIH Consensus Development Panel. Diagnosis and treatment of depression in late life. JAMA 1992;268:1018-24.
4. Zisselman MH, Rovner BW, Shmuely Y. Benzodiazepine use in the elderly prior to psychiatric hospitalisation. Psychosomatics 1996;37:38-42.
5. Flint AJ. The optimum duration of antidepressant treatment in the elderly. Int J Geriatr Psychiatry 1992;7:617-9.
6. Crome P. Drug compliance in the elderly. In: Wheatley D, editor. Psychopharmacology of old age. Oxford: Oxford University Press; 1982. p. 55-64.
7. Reynolds CF, Frank E, Kupfer DJ, Thase ME, Perel JM, Mazumdar S, et al. Treatment outcome in recurrent major depression: a post hoc comparison of elderly ("young old") and midlife patients. Am J Psychiatry 1996;153:1288-92.
8. Schneider LS. Pharmacologic considerations in the treatment of late-life depression. Am J Geriatr Psychiatry 1996;4(suppl 1):S51-S65.
9. Feighner JP. The role of venlafaxine in rational antidepressant therapy. J Clin Psychiatry 1994;55(9 suppl A):62-8.
10. Preskom S, Burke M: Somatic therapy for major depressive disorder. Selection of an antidepressant. J Clin Psychiatry 1992;53(suppl 9):1-14.
11. Roose SP, Dalack GW. Treating the depressed patient with cardiovascular problems. J Clin Psychiatry 1992;53(suppl 9):25-31.
12. Miller MD, Pollock BG, Rifai AH, Paradis C, Perel JM, George C, et al. Longitudinal analysis of nortriptyline side effects in elderly depressed patients. J Geriatr Psychiatry Neurol 1991;4:226-30.
13. Reynolds CK, Frank E, Perel JM, Miller MD, Paradis CF, Stack JA, et al. Nortriptyline side effects during double-blind, randomized, placebo-controlled maintenance therapy in older depressed patients. Am J Geriatr Psychiatry 1995;3:170-5.
14. Katz IR, Simpson GM, Curlick SM, Parmalee PA, Muhly C. Pharmacologic treatment of major depression for elderly patients in residential care settings. J Clin Psychiatry 1990;51(suppl 7):41-7.
15. Lipsey JR, Robinson RG, Pearlson GD, Rao K, Price TR. Nortriptyline treatment of post-stroke depression: a double-blind study. Lancet 1984;1:297-300.
16. Koenig HG, Breitner JCS. Use of antidepressants in medically ill older patients. Psychosomatics 1990;31:22-32.
17. Roose SP, Glassman AH. Antidepressant choice in the patient with cardiac disease: lessons from the cardiac arrhythmia suppression trial (CAST) studies. J Clin Psychiatry 1994;55(9 suppl A):83-7.
18. Rockwell E, Lam RW, Zisook S. Antidepressant drug studies in the elderly. Psychiatr Clin North Am 1988;11:215-33.
19. Thomas DR, Nelson DR, Johnson AM. Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology (Berl) 1987;93:193-200.
20. Geretsegger C, Bohmer F, Ludwig M. Paroxetine in the elderly depressed patient: randomised comparison with fluoxetine of efficacy, cognitive and behavioural effects. Int Clin Psychopharmacol 1994;9:25-9.
21. Grimsley SR, Jann MW. Paroxetine, sertraline and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharm 1992;11:930-57.
22. Laghrissi-Thode F, Pollock BG, Miller M, Altieri L, Kupfer DJ. Comparative effects of sertraline and nortriptyline on body sway in older depressed patients. Am J Geriatr Psychiatry 1995;3:217-28.
23. Liu BA, Mittmann N, Knowles SR, Shear NH. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports. Can Med Assoc J 1996;155:519-27.
24. Flint AJ, Crosby J, Genik JL. Recurrent hyponatremia associated with fluoxetine and paroxetine [letter]. Am J Psychiatry 1996;153:134.
25. Sheline YI, Freedland KE, Carney RM. How safe are serotonin reuptake inhibitors for depression in patients with coronary heart disease? Am J Med 1997;102:54-9.
26. Rickels K, Schweizer E. Clinical overview of serotonin reuptake inhibitors. J Clin Psychiatry 1990;51(12 suppl B):9-12.
27. Brown WA, Harrison W. Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? J Clin Psychiatry 1995;56:30-4.
28. McEntee WJ, Coffey DJ, Bondareff W, Alpert M, Raj AB, Rappaport SA, et al. A double-blind comparison of sertraline and nortriptyline in the treatment of depressed geriatric outpatients [poster]. American Psychiatric Association 148th annual meeting; 1995 May 20-25; Miami.
29. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153:311-20.
30. Newhouse PA. Use of serotonin selective reuptake inhibitors in geriatric depression. J Clin Psychiatry 1996;57a(suppl 5):12-22.
31. Shader RI, von Moltke LL, Schmider J, Harmatz JS, Greenblatt DJ. The clinician and drug interactions - an update. J Clin Psychopharmacol 1996;16:197-201.
32. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. J Clin Psychopharmacol 1996;16:345-55.
33. Preskorn SH. Recent pharmacologic advances in antidepressant therapy for the elderly. Am J Med 1993;94(suppl 5A):2S-12S.
34. De Vane CL. Pharmacokinetics of the selective serotonin reuptake inhibitors. J Clin Psychiatry 1992;53(suppl 2):13-20.
35. Harris MG, Benfield P. Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in older patients with depressive illness. Drugs Aging 1995;6(1):64-84.
36. De Vries MH, Raghoebar M, Mathlener IS, van Harten J. Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects. Ther Drug Monit 1992;14:493-8.
37. Warrington SJ. Clinical implications of the pharmacology of sertraline. Int Clin Psychopharmacol 1991;6(suppl 2):11-21.
38. Georgotas A, Thomas L, Forsell TL, Mann JJ, Kim M, Gershon S. Trazodone hydrochloride: a wide spectrum antidepressant with a unique pharmacological profile. A review of its neurochemical effects, pharmacology, clinical efficacy, and toxicology. Pharmacotherapy 1982;2:255-64.
39. Halper JP, Mann JJ. Cardiovascular effects of antidepressant medications. Br J Psychiatry 1988;153(suppl 3):87-98.
40. Goodnick PJ. Pharmacokinetic optimisation of therapy with newer antidepressants. Clin Pharmacokinet 1994;27:307-30.
41. Nutt D. Early action of nefazodone in anxiety associated with depression. J Psychopharmacol 1996;10(suppl 1):18-21.
42. Baldwin DS, Hawley CJ, Abed RT, Maragakis BP, Cox J, Buckingham SA, et al. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. J Clin Psychiatry 1996;57(suppl 2):46-52.
43. Barbhaiya RH, Buch AB, Greene DS. A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. J Clin Psychopharmacol 1996;16:19-25.
44. Robinson DS, Roberts DL, Smith JM, Stringfellow JC, Kaplita SB, Seminara JA, et al. The safety profile of nefazodone. J Clin Psychiatry 1996;57(suppl 2):31-8.
45. Van Laar MW, van Willigenburg APP, Volkerts ER. Acute and subchronic effects of nefazodone and imipramine on highway driving, cognitive functions, and daytime sleepiness in healthy adults and elderly subjects. J Clin Psychopharmacol 1995;15:30-40.
46. Georgotas A, McCue RE. The additional benefit of extending an antidepressant trial past seven weeks in the depressed elderly. Int J Geriatr Psychiatry 1989;4:191-5.
47. Prien RF, Kupfer DJ. Continuation drug therapy for major depressive episodes: How long should it be maintained? Am J Psychiatry 1986;143:18-23.
48. Georgotas A, McCue RE, Cooper TB, Nagachandran N, Chang I. How effective and safe is continuation therapy in elderly depressed patients? Arch Gen Psychiatry 1988;45:929-32.
49. Hirschfeld RMA. Longterm drug treatment of unipolar depression. Int Clin Psychopharmacol 1996;11:211-7.
50. Flint AJ, Rifat SL. The effect of treatment on the two-year course of late-life depression. Br J Psychiatry 1997;170:268-72.
51. Old Age Depression Interest Group. How long should the elderly take antidepressants? A double-blind placebo-controlled study of continuation/prophylaxis therapy with dothiepin. Br J Psychiatry 1993;162:175-82.
52. Sadavoy J, Reiman-Sheldon E. General hospital geriatric psychiatric treatment: a follow-up situay. J Am Geriatr Soc 1983;31:200-5.
53. Flint AJ, Rifat SL. The effect of sequential antidepressant treatment on geriatric depression. J Affect Disord 1996;36:95-105.
54. Flint AJ. Augmentation strategies in geriatric depression. Int J Geriatr Psychiatry 1995;10:137-46.
55. Thase ME, Rush AJ, Kasper S, Nemeroff CB. Tricylics and newer antidepressant medications: treatment options for treatment-resistant depressions. Depression 1994/1995;2:152-68.
56. Mulsant BH, Rosen J, Thornton JE, Zubenko GS. A prospective naturalistic study of electroconvulsive therapy in later-life depression. J Geriatr Psychiatry Neurol 1991;4:3-13.
57. Joffe RT, Levitt AJ, Sokolov STH, Young LT. Response to an open trial of a second SSRI in major depression. J Clin Psychiatry 1996;57:114-5.
58. Thase ME, Blomgren SL, Birkett MA, Apter JT, Tepner RG. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline.'J Clin Psychiatry 1997;58:16-21.
59. American Association for Geriatric Psychiatry. Recommendations for primary care physicians: when to refer depressed elderly patients to a geriatric psychiatrist. Bethesda (MD): The Association; 1997.